重症间质性肺疾病诊治的研究进展

doi:10.16352/j.issn.1001-6325.2026.06.0866

基础医学与临床 ›› 2026, Vol. 46 ›› Issue (6): 866-871.doi: 10.16352/j.issn.1001-6325.2026.06.0866

重症间质性肺疾病诊治的研究进展

田焦, 童瑾^*

重庆医科大学附属第二医院重症医学科, 重庆 400072

收稿日期:2025-04-12 修回日期:2025-09-24 出版日期:2026-06-05 发布日期:2026-05-27
通讯作者: ^*tongjin01234@163.com
基金资助:
重庆市自然科学基金(CSTB2024NSCQ-KJFZMSX0061)

Advances in the diagnosis and treatment of severe interstitial lung disease

TIAN Jiao, TONG Jin^*

Department of Critical Care Medicine, the Second Affiliated Hospital of Chongqing Medical University,Chongqing 400072,China

Received:2025-04-12 Revised:2025-09-24 Online:2026-06-05 Published:2026-05-27
Contact: ^*tongjin01234@163.com

摘要/Abstract

摘要： 重症间质性肺疾病(SILD)是一大类复杂且进展迅速的疾病,病死率极高,对SILD患者的早期诊断、评估和治疗至关重要。定量计算机断层扫描(QCT)、正电子发射计算机断层显像(PET/CT)、支气管肺泡灌洗液宏基因组二代测序(BALF-mNGS)在SILD诊断中的应用,有望提高诊断率和准确性。糖皮质激素/免疫抑制剂是治疗的基石,此外托法替布、抗纤维化药物和缺氧的管理在改善患者预后方面发挥重要作用,但仍需持续研究和制订个体化方案来为临床实践提供更坚实的依据和更多元的选择。

关键词: 间质性肺疾病, 急性加重, 肺纤维化, 诊断, 治疗

Abstract: Severe interstitial lung disease (SILD) is a large group of complex and rapidly progressing diseases with an extremely high mortality rate. Early diagnosis, assessment and treatment of patients with SILD are of critical importance. The application of quantitative computed tomography (QCT), positron emission tomography/computed tomography (PET/CT) and bronchoalveolar lavage fluid metagenomic next-generation sequencing (BALF-mNGS) in the diagnosis of SILD holds promise for improving diagnostic rates and accuracy. Glucocorticoids/immunosuppressants serve as the cornerstone of treatment, while tofacitinib, antifibrotic drugs and hypoxia management play significant roles in improving patient prognosis. However, continuous research and the development of individualized treatment strategy are still necessary to provide more solid evidence and more diverse options for clinical practice.

Key words: interstitial lung disease, acute exacerbation, pulmonary fibrosis, diagnosis, treatment

中图分类号:

R563.1

田焦, 童瑾. 重症间质性肺疾病诊治的研究进展[J]. 基础医学与临床, 2026, 46(6): 866-871.

TIAN Jiao, TONG Jin. Advances in the diagnosis and treatment of severe interstitial lung disease[J]. Basic & Clinical Medicine, 2026, 46(6): 866-871.

参考文献 22

[1]	Kim SH, Lee DH, Yang B, et al. Which factors are helpful for the early determination of treatment level in patients with interstitial lung disease in the intensive care unit to minimize the suffering in their end of life: a retrospective study[J]. Medicine (Baltimore), 2022, 101: e30524.doi:10.1097/MD.0000000000030524.
[2]	Zhang H, Li X, Zhang X, et al. Quantitative CT analysis of idiopathic pulmonary fibrosis and correlation with lung function study[J]. BMC Pulm Med, 2024, 24: 437. doi: 10.1186/s12890-024-03254-9.
[3]	Thillai M, Oldham JM, Ruggiero A, et al. Deep learning-based segmentation of computed tomography scans predicts disease progression and mortality in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2024, 210: 465-472.
[4]	Zhang Y, Chen Z, Long Y, et al. 18F-FDG PET/CT and HRCT: a combined tool for risk stratification in idiopathic inflammatory myopathy-associated interstitial lung disease[J]. Clin Rheumatol, 2022, 41: 3095-3105.
[5]	赵征,李坤鹏,王炎焱,等.18F脱氧葡萄糖-正电子发射断层扫描/CT对预测皮肌炎肺间质病变进展的研究[J]. 中华内科杂志, 2021, 60: 661-664.
[6]	Yang P, Luo Q, Wang X, et al. Comprehensive analysis of fibroblast activation protein expression in interstitial lung diseases[J]. Am J Respir Crit Care Med, 2023, 207: 160-172.
[7]	Sun H, Chen R, Li T, et al. Combination of transbron-chial cryobiopsy based clinic-radiologic-pathologic strategy and metagenomic next-generation sequencing for differen-tial diagnosis of rapidly progressive diffuse parenchymal lung diseases[J]. Front Cell Infect Microbiol, 2023, 13: 1204024. doi: 10.3389/fcimb.2023.1204024.
[8]	Zhan S, Li S, Cao Y, et al. Value of bronchoalveolar lavage fluid metagenomic next-generation sequencing in acute exacerbation of fibrosing interstitial lung disease: an individualized treatment protocol based on microbiological evidence[J]. BMC Pulm Med, 2024, 24: 400. doi: 10.1186/s12890-024-03216-1.
[9]	Hyung K, Lee JH, Kim JY, et al. Pulse versus non-pulse corticosteroid therapy in patients with acute exacerbation of idiopathic pulmonary fibrosis[J]. Respirology, 2024,29: 235-242.
[10]	Koshy K, Barnes H, Farrand E, et al. Steroid therapy in acute exacerbation of fibrotic interstitial lung disease[J]. Respirology, 2024, 29: 795-802.
[11]	Naccache JM, Jouneau S, Didier M, et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Respir Med, 2022,10: 26-34.
[12]	Shirai T, Machiyama T, Sato H, et al. Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis[J]. Clin Exp Rheumatol, 2023, 41: 291-300.
[13]	Wu W, Guo B, Sun W, et al. Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study[J]. Eur Respir J, 2025, 65: 2401488. doi: 10.1183/13993003.01488-2024.
[14]	Ida T, Furuta S, Takayama A, et al. Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis[J]. RMD Open, 2023, 9:e002795. doi: 10.1136/rmdopen-2022-002795.
[15]	Kato M, Sasaki S, Mori W, et al. Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world[J]. Sci Rep, 2023, 13: 12528. doi:10.1038/s41598-023-39101-w.
[16]	Inoue Y, Wells AU, Song JW, et al. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial[J]. Respirology, 2023,28: 465-474.
[17]	Kim JS, Murray S, Yow E, et al. Comparison of pirfenidone and nintedanib: post hoc analysis of the cleanup-IPF Study[J]. Chest, 2024, 165: 1163-1173.
[18]	Richeldi L, Azuma A, Cottin V, et al. Nerandomilast in patients with idiopathic pulmonary fibrosis[J]. N Engl J Med, 2025, 392: 2193-2202.
[19]	Maher TM, Assassi S, Azuma A, et al. Nerandomilast in patients with progressive pulmonary fibrosis[J]. N Engl J Med, 2025, 392: 2203-2214.
[20]	Corte TJ, Behr J, Cottin V, et al. Efficacy and safety of admilparant, an LPA(1) antagonist, in pulmonary fibrosis: a phase 2 randomized clinical trial[J]. Am J Respir Crit Care Med, 2025,211: 230-238.
[21]	Lancaster L, Cottin V, Ramaswamy M, et al. Bexotegrast in patients with idiopathic pulmonary fibrosis: the INTEGRIS-IPF clinical trial[J]. Am J Respir Crit Care Med, 2024, 210: 424-434.
[22]	Tonelli R,Castaniere I, Cortegiani A, et al. Inspiratory effort and respiratory mechanics in patients with acute exacerbation of idiopathic pulmonary fibrosis: a preliminary matched control study. pulmonology, 2023, 29: 469-477.

重症间质性肺疾病诊治的研究进展

Advances in the diagnosis and treatment of severe interstitial lung disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 22

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘睿琦, 张建民, 何维, 陈慧. FBXO2是Vδ1 γδ T细胞识别的肿瘤相关异位蛋白质配体[J]. 基础医学与临床, 2026, 46(7): 887-894.
[2]	甄宏楠, 王方, 肖嘉宁, 姜斐, 张园, 沈晶. 基线营养状态与宫颈癌放射治疗导致的慢性不良反应的关系[J]. 基础医学与临床, 2026, 46(7): 998-1003.
[3]	刘翠玲, 于树娜. NLRP3炎性小体在肝缺血/再灌注损伤中作用的研究进展[J]. 基础医学与临床, 2026, 46(7): 1004-1008.
[4]	耿睿婕, 姑丽尼格尔·库来西, 张建军, 贾尔肯阿依·阿不都拉依, 高扬, 寇新红. 非哺乳期乳腺炎患者外周血及单核细胞来源HMGB1水平与病情相关[J]. 基础医学与临床, 2026, 46(6): 855-860.
[5]	高艺丹, 郭丽娜, 王爽, 张红, 宋婉璐, 胡宇飞, 杨沛然. 博来霉素联合猪胰弹性蛋白酶诱导的小鼠肺纤维化合并肺气肿模型的建立[J]. 基础医学与临床, 2026, 46(6): 800-806.
[6]	刘承国, 李露, 邹川. 氧化应激在急性脑损伤发病机制中的作用[J]. 基础医学与临床, 2026, 46(5): 721-725.
[7]	郑泽延, 周智博, 孙宇欣, 郭晓湲, 朱惠娟, 潘慧. 生长激素治疗对生长激素缺乏症患儿血清抵抗素、瘦素及FGF-23水平的影响[J]. 基础医学与临床, 2026, 46(5): 687-693.
[8]	宋玥洋, 施亚君, 余茜, 闻应时, 孙淼. Cantu综合征合并22q11.2重复综合征1例[J]. 基础医学与临床, 2026, 46(4): 561-565.
[9]	袁策, 叶萃萃, 郭长安, 罗来升, 柳月珍. 中性粒细胞胞外诱捕网在脓毒症相关急性肺损伤中的作用[J]. 基础医学与临床, 2026, 46(4): 597-601.
[10]	刘靖靖, 李燕. 脂肪酸代谢重编程在弥漫性大B细胞淋巴瘤中的研究进展[J]. 基础医学与临床, 2026, 46(4): 582-586.
[11]	刘芃芃, 孙昭, 邱维, 唐辉, 朱文佳, 王文惠, 王颖轶. 局部放射治疗对酪氨酸激酶抑制剂治疗非小细胞肺癌伴寡残留病变的影响[J]. 基础医学与临床, 2026, 46(4): 491-497.
[12]	张振, 杨连任, 扈俊坤, 张伟, 梁伟. 血清D-二聚体水平在评估非小细胞肺癌患者化疗效果及预后的价值[J]. 基础医学与临床, 2026, 46(3): 417-420.
[13]	詹森, 刘宇杰, 李天康, 张冲, 任泽强, 张易. 结直肠癌患者血浆外泌体中circGAPVD1高表达与病情相关[J]. 基础医学与临床, 2026, 46(3): 374-380.
[14]	刘肇一, 尹美玲, 王琳, 周巾煜. 血浆IgG N-糖肽绝对定量方法用于筛选早期慢性阻塞性肺疾病诊断标志物[J]. 基础医学与临床, 2026, 46(3): 332-338.
[15]	袁佳敏, 方成超, 江君生. 巨噬细胞胞外诱捕网在感染性疾病中的作用[J]. 基础医学与临床, 2026, 46(3): 450-455.